Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;23(10):781-799.
doi: 10.2174/1389200223666220608144551.

Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review

Affiliations
Review

Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review

Lahanya Guha et al. Curr Drug Metab. 2022.

Abstract

Breast cancer is the most prevalent cancer in women around the world, having a sudden spread nowadays because of the poor sedentary lifestyle of people. Comprising several subtypes, one of the most dangerous and aggressive ones is triple-negative breast cancer or TNBC. Even though conventional surgical approaches like single and double mastectomy and preventive chemotherapeutic approaches are available, they are not selective to cancer cells and are only for symptomatic treatment. A new branch called nanotechnology has emerged in the last few decades that offers various novel characteristics, such as size in nanometric scale, enhanced adherence to multiple targeting moieties, active and passive targeting, controlled release, and site-specific targeting. Among various nanotherapeutic approaches like dendrimers, lipid-structured nanocarriers, carbon nanotubes, etc., nanoparticle targeted therapeutics can be termed the best among all for their specific cytotoxicity to cancer cells and increased bioavailability to a target site. This review focuses on the types and molecular pathways involving TNBC, existing treatment strategies, various nanotechnological approaches like exosomes, carbon nanotubes, dendrimers, lipid, and carbon-based nanocarriers, and especially various nanoparticles (NPs) like polymeric, photodynamic, peptide conjugated, antibody-conjugated, metallic, inorganic, natural product capped, and CRISPR based nanoparticles already approved for treatment or are under clinical and pre-clinical trials for TNBC.

Keywords: Triple-negative breast cancer; estrogen receptor (ER); human epidermal growth factor receptor 2 (HER2); nanoparticles; nanotechnology; progesterone receptor (PR); targeted therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cooper G.M.S.M.; The Cell: A Molecular Approach Sinauer Associates, 2000.
    1. Skuse A.; Definition, diagnosis and cause: Ravenous natures. Constructions of Cancer in Early Modern 2015
    1. Manjunath M.; Choudhary B.; Triple-negative breast cancer: A run-through of features, classification and current therapies. Oncol Lett 2021,22(1),512 - DOI - PubMed
    1. Breast Cancer Treatment (Adult). 2020. Available from:
    1. Shafi S.; Khan S.; Hoda F.; Fayaz F.; Singh A.; Khan M.A.; Ali R.; Pottoo F.H.; Tariq S.; Najmi A.K.; Decoding novel mechanisms and emerging therapeutic strategies in breast cancer resistance. Curr Drug Metab 2020,21(3),199-210 - DOI - PubMed